Regeneron Pharmaceuticals, Inc. (0R2M.L)

892,85 -4,44 (-0,49%) Börsenschluss: 05:14PM BST

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 13.450

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Leonard S. Schleifer M.D., Ph.D.	Co-Founder, President, CEO & Co-Chairman	7M	N/A	1953
Dr. George D. Yancopoulos M.D., Ph.D.	Co-Founder, President, Chief Scientific Officer & Co-Chairman	6,59M	N/A	1960
Dr. Andrew J. Murphy Ph.D.	Executive Vice President of Research	1,62M	19,39M	1959
Mr. Daniel P. Van Plew	Executive VP and GM of Industrial Operations & Product Supply	1,95M	45,28M	1973
Ms. Marion E. McCourt	Executive Vice President of Commercial	1,5M	4,25M	1960
Mr. Christopher R. Fenimore CPA	Senior VP of Finance & CFO	N/A	N/A	1971
Ms. Patrice Gilooly	Senior Vice President of Quality Assurance & Operations	N/A	N/A	N/A
Mr. Bob McCowan	Senior VP of IT & Chief Information Officer	N/A	N/A	N/A
Mr. Ryan Crowe	Senior Vice President of Investor Relations & Strategic Analysis	N/A	N/A	N/A
Mr. Joseph J. LaRosa	Executive VP, General Counsel & Secretary	1,75M	23,23M	1959

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 10, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.